Johns Hopkins ABX Guide
Atovaquone
INDICATIONS
FDA
FDA
- Prevention of Pneumocystis jirovecii pneumonia in patients who are intolerant to TMP/SMX
- Oral treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (second or third line)
- Prevention and treatment of malaria (in combination with proguanil: see separate module)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Toxoplasmosis treatment alone (limited data with atovaquone 750 mg four times a day in adults)
- Toxoplasmosis treatment in combination with pyrimethamine or sulfadiazine
- Babesiosis (in combination with azithromycin)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: April 8, 2019
Citation
Smith, Janessa M, and Paul A Pham. "Atovaquone." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/6/Atovaquone.
Smith JM, Pham PA. Atovaquone. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/6/Atovaquone. Accessed December 5, 2024.
Smith, J. M., & Pham, P. A. (2019). Atovaquone. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/6/Atovaquone
Smith JM, Pham PA. Atovaquone [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2024 December 05]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/6/Atovaquone.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Atovaquone
ID - 540038
A1 - Smith,Janessa,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2019/04/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/6/Atovaquone
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
